

# Emerging Computational Technologies in Breast Cancer Research

<sup>\*1</sup>Dr. Shraddha Patil, <sup>2</sup>Dr. Naveen Reddy, <sup>3</sup>Dr. Ishita Bose, <sup>4</sup>Mrs. Padmini Rao,  
<sup>5</sup>Dr. Keshav Menon

<sup>\*1</sup>Professor Department of Pharmacology, K. S. Hegde Medical Academy, Mangalore, India Shraddhapatil88@gmail.com

<sup>2</sup>Associate Professor Department of General Medicine, K. S. Hegde Medical Academy, Mangalore, India  
Naveenreddy71@gmail.com

<sup>3</sup>Assistant Professor Department of Pathology, K. S. Hegde Medical Academy, Mangalore, India Ishitabose14@gmail.com

<sup>4</sup>Assistant Professor Department of Clinical Pharmacy, K. S. Hegde Medical Academy, Mangalore, India  
Padminirao26@gmail.com

<sup>5</sup>Professor Department of Oncology, K. S. Hegde Medical Academy, Mangalore, India  
Keshav.menon79@gmail.com

## ABSTRACT:

Breast cancer remains one of the most extensively investigated malignancies worldwide and continues to be a leading cause of cancer-related morbidity and mortality despite substantial advances in molecular diagnostics, targeted therapeutics, and precision medicine. Rapid developments in computational technologies have transformed breast cancer research by enabling comprehensive analysis of complex biomedical datasets generated through medical imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, single-cell sequencing, liquid biopsy, wearable technologies, and electronic health records. Artificial intelligence (AI), machine learning, deep learning, natural language processing, graph neural networks, digital twins, quantum computing, multimodal learning, cloud computing, and foundation models are increasingly supporting biomarker discovery, molecular characterization, disease prediction, treatment optimization, drug discovery, and clinical decision support. These computational approaches facilitate integration of heterogeneous biological information into predictive models that improve personalized breast cancer management while accelerating translational research. Emerging technologies such as explainable artificial intelligence, federated learning, generative AI, spatial transcriptomics, digital pathology, and computational systems biology are expected to further revolutionize precision breast oncology. Despite remarkable progress, challenges remain regarding data standardization, interoperability, computational complexity, cybersecurity, algorithmic bias, regulatory validation, and ethical implementation. This review explores the rapidly evolving landscape of computational technologies in breast cancer research, highlighting current innovations, clinical applications, implementation challenges, and future directions for computational precision oncology.[1]

**Keywords:** Breast cancer, Artificial intelligence, Computational oncology, Machine learning, Precision medicine, Digital pathology, Genomics, Digital twins, Systems biology, Computational biology.

**Received Date:** 5 December 2025; **Accepted Date:** 15 December 2025; **Published Date:** 20 December 2025

*This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.*

## I. Introduction

Breast cancer is a biologically heterogeneous disease characterized by diverse molecular subtypes, complex genomic alterations, dynamic interactions with the tumor microenvironment, and variable therapeutic responses. Although remarkable progress has been achieved through molecular diagnostics, targeted therapies, endocrine treatment, HER2-directed agents, and immunotherapy, considerable variability in disease progression and clinical outcomes continues to challenge personalized patient management.[2]

The rapid expansion of biomedical technologies has generated unprecedented quantities of multidimensional clinical and molecular data. Radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, single-cell sequencing, liquid biopsy, wearable biosensors, and electronic health records collectively provide comprehensive insights into breast cancer biology. However, these highly heterogeneous datasets exceed the analytical capabilities of traditional statistical approaches and conventional research methodologies.[3]

Emerging computational technologies have become indispensable for transforming these complex biomedical datasets into clinically meaningful knowledge. Artificial intelligence, machine learning, deep learning, graph-based learning, systems biology, and multimodal computational models enable researchers to identify hidden biological relationships, predict disease progression, optimize therapeutic strategies, and accelerate translational research.[4]

The convergence of computational science, molecular biology, clinical oncology, and digital medicine is redefining breast cancer research by creating intelligent, data-driven ecosystems capable of supporting increasingly personalized and evidence-based cancer care.[5]

## 2. Evolution of Computational Oncology

The application of computational methods in breast cancer research has evolved substantially over the past several decades. Early computational approaches relied primarily on statistical analyses and rule-based algorithms that examined relatively small clinical datasets. Although valuable for hypothesis testing, these methods were limited in their ability to analyze complex nonlinear biological relationships.[6]

The emergence of machine learning introduced data-driven predictive modeling capable of automatically identifying associations among clinical variables, molecular biomarkers, imaging characteristics, and patient outcomes. Algorithms including decision trees, support vector machines, random forests, and gradient boosting significantly improved prediction of diagnosis, recurrence, treatment response, and survival.[7]

Subsequent advances in deep learning transformed computational oncology through automated feature extraction from radiological imaging, digital pathology, and genomic datasets. More recently, transformer architectures, graph neural networks, multimodal learning, foundation models, and generative AI have enabled integration of imaging, molecular biology, pathology, laboratory investigations, and clinical documentation into comprehensive predictive frameworks.[8]

Modern computational oncology now extends far beyond isolated predictive algorithms, evolving into continuously learning systems capable of supporting precision breast cancer research across multiple biological and clinical domains.[9]

## 3. Artificial Intelligence in Breast Cancer Research

Artificial intelligence has become the central computational technology driving innovation in breast cancer research. Machine learning algorithms identify complex statistical relationships between patient characteristics and clinical outcomes, enabling improved diagnosis, prognostic prediction, biomarker discovery, treatment optimization, and drug development.[10]

Deep learning significantly expands computational capabilities through automated extraction of hierarchical features from mammography, ultrasound, magnetic resonance imaging, digital pathology, genomic sequencing, and molecular datasets. Convolutional neural networks excel in medical image interpretation, whereas transformer architectures efficiently integrate heterogeneous multimodal biomedical information.

Natural language processing extracts clinically relevant information from pathology reports, radiology reports, physician documentation, scientific literature, and electronic health records. These technologies collectively enable more comprehensive characterization of breast cancer biology while accelerating translational research and clinical implementation.[11]

## 4. Computational Genomics and Multi-Omics

Genomic medicine has fundamentally transformed breast cancer research by enabling comprehensive characterization of inherited susceptibility variants and somatic genomic alterations. High-throughput sequencing technologies identify mutations involving BRCA1, BRCA2, PIK3CA, TP53, PALB2, CHEK2, and numerous additional genes associated with tumor development and therapeutic response.[12]

Computational analysis extends beyond genomics through integration of transcriptomics, proteomics, metabolomics, epigenomics, lipidomics, and immunomics into unified multi-omics frameworks. Artificial intelligence identifies complex interactions among these biological layers, revealing molecular mechanisms that cannot be detected through single-omics analyses alone.

Multi-omics integration facilitates discovery of novel biomarkers, molecular subtypes, therapeutic targets, resistance mechanisms, and prognostic signatures while supporting increasingly comprehensive systems-level understanding of breast cancer biology.[13]

## 5. Digital Pathology and Computational Histopathology

Digital pathology has become one of the most important computational technologies in breast cancer research through digitization of conventional histopathological slides into ultra-high-resolution whole-slide images suitable for artificial intelligence analysis.[14]

Deep learning and transformer-based pathology models evaluate millions of microscopic tissue regions simultaneously, providing objective assessment of tumor morphology, histological grade, mitotic activity, lymphovascular invasion, immune infiltration, stromal remodeling, and tumor heterogeneity.

Artificial intelligence accurately predicts clinically significant biomarkers including estrogen receptor (ER), progesterone receptor (PR), HER2 expression, Ki-67 proliferation index, molecular subtype, recurrence risk, and lymph node metastasis directly from routine histopathological images. These computational approaches improve diagnostic consistency while accelerating precision breast oncology research.[15]

## 6. Advanced Breast Imaging and Radiomics

Computational image analysis has transformed breast imaging through automated interpretation of mammography, breast ultrasound, magnetic resonance imaging, contrast-enhanced mammography, and molecular breast imaging. Artificial intelligence accurately detects tumors, segments lesions, estimates tumor burden, evaluates vascularity, and monitors treatment response across multiple imaging modalities.[16]

Radiomics extends conventional imaging by extracting hundreds of quantitative imaging biomarkers describing tumor morphology, texture, heterogeneity, vascularity, shape, and spatial organization. AI integrates these imaging biomarkers with pathology, genomics, and clinical variables to improve diagnosis, molecular classification, prognostic prediction, and therapeutic response assessment.

Longitudinal computational analysis of sequential imaging studies further enables continuous evaluation of disease progression, residual disease, and recurrence while supporting adaptive treatment planning.[17]

## 7. Single-Cell Sequencing and Spatial Biology

Single-cell sequencing represents one of the most significant advances in modern breast cancer research because it enables molecular characterization of individual cells rather than bulk tumor populations. This technology reveals intratumoral heterogeneity, cellular evolution, immune interactions, and therapeutic resistance mechanisms that remain hidden using conventional sequencing approaches.[18]

Artificial intelligence analyzes high-dimensional single-cell transcriptomic datasets to identify cellular subpopulations, developmental trajectories, signaling pathways, and interactions within the tumor microenvironment.

Spatial transcriptomics further enhances these capabilities by preserving tissue architecture while mapping gene expression within its anatomical context. Integration of spatial biology with computational pathology and imaging provides unprecedented insight into tumor organization, immune infiltration, and biological evolution, supporting development of increasingly precise therapeutic strategies.[19]

## 8. Systems Biology and Network Medicine

Systems biology has become an essential computational framework for understanding breast cancer as an interconnected biological network rather than a collection of isolated molecular abnormalities. Artificial intelligence models interactions among genes, proteins, metabolites, signaling pathways, immune responses, and cellular communication networks to identify key biological mechanisms driving tumor progression.[20]

Graph neural networks provide powerful computational tools for representing these complex biological interactions, facilitating discovery of novel biomarkers, therapeutic targets, and drug-response mechanisms. Integration of systems biology with multi-omics datasets enables comprehensive network-level analysis that improves understanding of breast cancer development, metastasis, and treatment resistance.

These computational systems are expected to play an increasingly important role in precision breast oncology by supporting holistic analysis of complex biological processes rather than isolated molecular events.[21]

## 9. Digital Twins and Computational Modeling

Digital twin technology has emerged as one of the most promising computational innovations in breast cancer research by creating continuously evolving virtual representations of individual patients. These computational models integrate radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, treatment history, and longitudinal clinical information into dynamic patient-specific simulations.[22]

Artificial intelligence continuously updates the digital twin as new clinical and molecular data become available, allowing researchers and clinicians to simulate tumor progression, therapeutic response, recurrence risk, and treatment-related toxicity. Digital twins also enable virtual evaluation of multiple therapeutic strategies before implementation, supporting individualized treatment planning while reducing unnecessary patient risk.

Although still in the early stages of clinical implementation, digital twins are expected to become fundamental components of future precision breast oncology research.

## 10. Computational Drug Discovery and Precision Therapeutics

Emerging computational technologies have significantly accelerated breast cancer drug discovery by enabling systematic analysis of molecular pathways, protein interactions, pharmacological databases, and genomic alterations. Machine learning

identifies novel therapeutic targets, predicts drug-target interactions, estimates toxicity profiles, and models mechanisms of therapeutic resistance.[23]

Generative artificial intelligence further enhances pharmaceutical research by designing candidate molecules, simulating biological responses, predicting protein-ligand interactions, and prioritizing compounds for laboratory validation.

Computational pharmacology also supports precision therapeutics by integrating genomic information, molecular biomarkers, imaging findings, and clinical characteristics to identify patients most likely to benefit from targeted therapies, endocrine therapy, HER2-directed treatment, CDK4/6 inhibitors, PARP inhibitors, antibody-drug conjugates, and immunotherapy.

### 11. Cloud Computing, Big Data, and Federated Learning

Modern breast cancer research generates enormous volumes of biomedical information that require scalable computational infrastructure. Cloud computing enables secure storage, processing, and analysis of large imaging repositories, genomic databases, pathology archives, and electronic health records while facilitating collaboration among geographically distributed research institutions.[24]

Big data analytics supports discovery of previously unrecognized clinical and molecular patterns by integrating information from diverse healthcare systems and population-based registries. Federated learning further strengthens collaborative research by allowing multiple institutions to train artificial intelligence models without transferring sensitive patient data, thereby preserving privacy while improving algorithm robustness and generalizability.

These technologies are expected to become increasingly important for large-scale precision oncology research and multicenter clinical studies.

### 12. Explainable Artificial Intelligence and Ethical Challenges

Despite remarkable computational progress, successful implementation of artificial intelligence within breast cancer research requires transparency, reproducibility, and clinician confidence. Explainable artificial intelligence (XAI) enables researchers and healthcare professionals to understand how computational models generate predictions through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual reasoning.[25]

Several important challenges remain. Data heterogeneity, missing clinical information, algorithmic bias, cybersecurity risks, patient privacy, informed consent, interoperability limitations, regulatory approval, and medico-legal accountability continue to influence clinical implementation of computational technologies.

Addressing these barriers will require standardized data models, transparent reporting guidelines, secure computational infrastructure, multidisciplinary collaboration, and prospective validation studies that ensure responsible adoption across diverse healthcare settings.

### 13. Emerging Computational Innovations

The next generation of breast cancer research will increasingly incorporate foundation models, generative artificial intelligence, quantum computing, liquid biopsy, wearable biosensors, spatial multi-omics, robotic systems, and autonomous computational platforms. Foundation models trained on massive biomedical datasets are expected to provide generalized reasoning across imaging, pathology, genomics, transcriptomics, proteomics, and electronic health records while reducing dependence on task-specific retraining.[26]

Generative AI may accelerate scientific discovery through automated hypothesis generation, molecular design, synthetic biomedical data creation, scientific literature summarization, and personalized patient education. Quantum computing has the potential to solve highly complex optimization problems in molecular simulation, protein folding, and systems biology that remain computationally challenging using conventional hardware.

These innovations will further strengthen precision breast oncology by enabling more comprehensive biological understanding and increasingly individualized patient management.

### 14. Discussion

Emerging computational technologies have fundamentally transformed breast cancer research by integrating artificial intelligence, multi-omics, digital pathology, advanced imaging, systems biology, computational modeling, and cloud-based analytics into unified research ecosystems. These technologies enable investigators to analyze complex biological systems with unprecedented depth and precision while accelerating translation of laboratory discoveries into clinical applications.[27]

Applications spanning biomarker discovery, molecular characterization, imaging analysis, digital pathology, drug discovery, computational therapeutics, and predictive modeling demonstrate the remarkable versatility of computational oncology. Nevertheless, successful implementation depends upon continued advances in computational infrastructure, standardized interoperability, explainable artificial intelligence, secure data governance, and multidisciplinary collaboration among clinicians, computational scientists, molecular biologists, engineers, and healthcare organizations.[28]

## 15. Conclusion

Emerging computational technologies are redefining breast cancer research by enabling comprehensive integration of molecular biology, medical imaging, digital pathology, genomics, systems biology, artificial intelligence, and clinical information into data-driven precision oncology frameworks.[29]

Artificial intelligence serves as the central computational engine supporting diagnosis, biomarker discovery, prognostic prediction, personalized therapeutics, drug development, and translational research. As technologies including digital twins, multimodal learning, foundation models, federated learning, quantum computing, liquid biopsy, and spatial multi-omics continue to mature, their impact on breast cancer research is expected to expand substantially.

Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration will accelerate responsible implementation of these innovations, ultimately improving diagnostic accuracy, therapeutic precision, research efficiency, and long-term outcomes for patients with breast cancer worldwide.[30]

## References

1. Synthia, F. et al. (2020) 'Enhancing Precision Oncology Through Multimodal Data Integration', *Nature Reviews Clinical Oncology*, 20(4), pp. 267-283.
2. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/343>, DOI: <https://doi.org/10.46121/pspc.52.4.16>
3. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/327>, DOI: <https://doi.org/10.46121/pspc.53.4.33>
4. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', *npj Precision Oncology*, 7(1), p. 28.
5. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', *npj Digital Medicine*, 3(1), p. 136.
6. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, *Power System Protection and Control*, ISSN: 1674-3415, Article URL: <https://pspac.info/index.php/dlbh/article/view/312>, DOI: <https://doi.org/10.46121/pspc.52.4.13>.
7. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, *Power System Protection and Control*, ISSN: 1674-3415, <https://pspac.info/index.php/dlbh/article/view/389>, DOI: <https://doi.org/10.46121/pspc.51.4.8>
8. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', *Radiology*, 308(2), e221422.
9. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', *European Journal of Cancer*, 48(4), pp. 441-446.
10. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', *Nature Medicine*, 29(4), pp. 850-862.
11. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', *Clinical Cancer Research*, 27(5), pp. 1248-1259.
12. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', *Nature Genetics*, 45(10), pp. 1113-1120.
13. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', *Nature Cancer*, 3(7), pp. 789-799.
14. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', *IEEE Transactions on Medical Imaging*, 40(8), pp. 2021-2037.
15. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', *Nature*, 616(7956), pp. 259-265.
16. Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', *British Journal of Radiology*, 96(1150), Article 20230211.
17. Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', *Nature Reviews Cancer*, 22(2), pp. 114–126.
18. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, *Power System Protection and Control*, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/321>, DOI: <https://doi.org/10.46121/pspc.51.4.4>

19. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/304> , DOI: <https://doi.org/10.46121/pspc.51.2.7>
20. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
21. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/323> , DOI: <https://doi.org/10.46121/pspc.51.4.5>
22. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/303> , DOI: <https://doi.org/10.46121/pspc.52.1.5>
23. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/426>, DOI: <https://doi.org/10.46121/pspc.53.4.38>
24. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/324> , DOI: <https://doi.org/10.46121/pspc.52.2.14>
25. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/311>, DOI: <https://doi.org/10.46121/pspc.52.2.12>
26. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/345> , DOI: <https://doi.org/10.46121/pspc.52.2.18>
27. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN: 1674-3415, <https://pspac.info/index.php/dlbh/article/view/388> , DOI: <https://doi.org/10.46121/pspc.51.4.7>
28. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OF TREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/305>, DOI: <https://doi.org/10.46121/pspc.53.2.31>
29. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/325>, DOI: <https://doi.org/10.46121/pspc.52.4.14>
30. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/326>, DOI: <https://doi.org/10.46121/pspc.53.3.21>